Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA Vaccine

Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern

Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., O’Connell, A.-M., et al. (2021) · doi:10.1101/2021.12.14.21267615 · Cited by 2,420 · see citing works

Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa

Viana, R. P. E. S., Moyo, S. M., Amoako, D. G., Tegally, H., Scheepers, C., Althaus, C. L., Anyaneji, U. J., Bester, P. A., Boni, M. F., Chand, M., et al. (2022) · Nature · doi:10.1038/s41586-022-04411-y · Cited by 1,653 · see citing works

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Gilbert, P. B., Montefiori, D. C., McDermott, A. B., Fong, Y., Benkeser, D., Deng, W., Zhou, H., Houchens, C. R., Martins, K., Jayashankar, L., et al. (2022) · Science · doi:10.1126/science.abm3425 · Cited by 1,137 · see citing works

SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons

Rössler, A., Riepler, L., Bante, D., von Laer, D., & Kimpel, J. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119236 · Cited by 466 · see citing works

Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study

Hansen, C. H., Schelde, A. B., Moustsen-Helm, I. R., Emborg, H.-D., Krause, T. G., Mølbak, K., & Valentiner-Branth, P. (2021) · doi:10.1101/2021.12.20.21267966 · Cited by 133 · see citing works

Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2

Lassaunière, R., Polacek, C., Gram, G., Frische, A., Tingstedt, J., Krüger, M., Dorner, B., Cook, A., Brown, R., Orekov, T., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00419-z · Cited by 25 · see citing works

Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study

Adams, K., Rhoads, J. P., Surie, D., Gaglani, M., Ginde, A. A., McNeal, T., Talbot, H. K., Casey, J. D., Zepeski, A., Shapiro, N. I., et al. (2022) · BMJ · doi:10.1136/bmj-2022-072065 · Cited by 115 · see citing works

Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2

Firouzabadi, N., Ghasemiyeh, P., Moradishooli, F., & Mohammadi‐Samani, S. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109968 · Cited by 100 · see citing works

COVID-19 in 2022—The Beginning of the End or the End of the Beginning?

del Rı́o, C., & Malani, P. (2022) · JAMA · doi:10.1001/jama.2022.9655 · Cited by 77 · see citing works

Adjuvantation of a SARS-CoV-2 mRNA vaccine with controlled tissue-specific expression of an mRNA encoding IL-12p70

Brook, B., Duval, V., Barman, S., Speciner, L., Sweitzer, C., Khanmohammed, A., Menon, M., Foster, K., Ghosh, P., Abedi, K., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adm8451 · Cited by 44 · see citing works

Vaccine‐induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster

Favresse, J., Gillot, C., Bayart, J., David, C., Simon, G., Wauthier, L., Closset, M., Dogné, J., & Douxfils, J. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28164 · Cited by 33 · see citing works

Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis

Rahman, M. O., Kamigaki, T., Thandar, M. M., Haruyama, R., Yan, F., Shibamura-Fujiogi, M., Khin Maung Soe, J., Islam, M. R., Yoneoka, D., Miyahara, R., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-076892 · Cited by 29 · see citing works

Mechanistic model for booster doses effectiveness in healthy, cancer, and immunosuppressed patients infected with SARS-CoV-2

Voutouri, C., Hardin, C. C., Naranbhai, V., Nikmaneshi, M. R., Khandekar, M. J., Gainor, J. F., Stylianopoulos, T., Munn, L. L., & Jain, R. K. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2211132120 · Cited by 29 · see citing works

Optimization and evaluation of a live virus SARS-CoV-2 neutralization assay

Frische, A., Brooks, P. T., Gybel‐Brask, M., Sækmose, S. G., Jensen, B. A., Mikkelsen, S., Bruun, M. T., Boding, L., Polacek, C., Jørgensen, C. S., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272298 · Cited by 22 · see citing works

Efficacy of three COVID-19 vaccine doses in lung transplant recipients: a multicentre cohort study

Dauriat, G., Beaumont, L., Nguyen, L. B. L., Renaud-Picard, B., Penhouet, M., Coiffard, B., Salpin, M., Demant, X., Raymond, C. S., Carlier, N., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.00502-2022 · Cited by 22 · see citing works

Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease: a prospective cohort study

Simón, D., Taşçılar, K., Fagni, F., Kleyer, A., Krönke, G., Meder, C. H., Dietrich, P., Orlemann, T., Mößner, J., Taubmann, J., et al. (2022) · The Lancet Rheumatology · doi:10.1016/s2665-9913(22)00191-6 · Cited by 16 · see citing works

SARS-CoV-2 elicits non-sterilizing immunity and evades vaccine-induced immunity: implications for future vaccination strategies

Beukenhorst, A. L., Koch, C. M., Hadjichrysanthou, C., Alter, G., de Wolf, F., Anderson, R. M., & Goudsmit, J. (2023) · European Journal of Epidemiology · doi:10.1007/s10654-023-00965-x · Cited by 17 · see citing works

Low Spike Antibody Levels and Impaired BA.4/5 Neutralization in Patients with Multiple Myeloma or Waldenstrom’s Macroglobulinemia after BNT162b2 Booster Vaccination

Rosati, M., Terpos, E., Bear, J., Burns, R. T., Devasundaram, S., Ntanasis‐Stathopoulos, I., Gavriatopoulou, M., Kastritis, E., Dimopoulos, M. A., Pavlakis, G. N., et al. (2022) · Cancers · doi:10.3390/cancers14235816 · Cited by 15 · see citing works

Polyfunctional antibodies: a path towards precision vaccines for vulnerable populations

Purcell, R. A., Theisen, R. M., Arnold, K. B., Chung, A. W., & Selva, K. J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1183727 · Cited by 15 · see citing works

Characterization and Utilization of Disulfide-Bonded SARS-CoV-2 Receptor Binding Domain of Spike Protein Synthesized by Wheat Germ Cell-Free Production System

Yamaoka, Y., Jeremiah, S. S., Funabashi, R., Miyakawa, K., Morita, T., Mihana, Y., Kato, H., & Ryo, A. (2022) · Viruses · doi:10.3390/v14071461 · Cited by 13 · see citing works

An inactivated recombinant rabies virus chimerically expressed RBD induces humoral and cellular immunity against SARS-CoV-2 and RABV

Zhang, H., Jin, H., Yan, F., Song, Y., Dai, J., Jiao, C., Bai, Y., Sun, J., Liu, D., Wang, S., et al. (2022) · Virologica Sinica · doi:10.1016/j.virs.2022.12.006 · Cited by 11 · see citing works

DNA origami vaccine nanoparticles improve humoral and cellular immune responses to infectious diseases

Zeng, Y. C., Young, O. J., Xiong, Q., Si, L., Ku, M., Bernier, S. G., Dembele, H., Isinelli, G., Gilboa, T., Swank, Z., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01614-w · Cited by 28 · see citing works

The BNT162b2 mRNA vaccine demonstrates reduced age-associated TH1 support in vitro and in vivo

Brook, B., Fatou, B., Barman, S., Barman, S., Sweitzer, C., Bosco, A.-N., Sherman, A., Baden, L., Morrocchi, E., Sánchez‐Schmitz, G., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111055 · Cited by 15 · see citing works

Antibody Response after SARS-CoV-2 Infection with the Delta and Omicron Variant

Błaszczuk, A., Michalski, A., Sikora, D., Malm, M., Drop, B., & Polz-Dacewicz, M. (2022) · Vaccines · doi:10.3390/vaccines10101728 · Cited by 10 · see citing works

Efficacy of a stable broadly protective subunit vaccine platform against SARS-CoV-2 variants of concern

Garg, R., Liu, Q., van Kessel, J., Asavajaru, A., Uhlemann, E.-M. E., Joessel, M., Hamonic, G., Khatooni, Z., Kroeker, A., Lew, J. M., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.05.028 · Cited by 8 · see citing works

Overview of COVID-19 Infection, Treatment, and Prevention in Children

Kao, C. M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020424 · Cited by 9 · see citing works

Korean Red Ginseng Potentially Improves Maintaining Antibodies after COVID-19 Vaccination: A 24-Week Longitudinal Study

Yoon, J., Park, B., Kim, H., Choi, S. J., & Jung, D. (2023) · Nutrients · doi:10.3390/nu15071584 · Cited by 7 · see citing works

Kinetics and ability of binding antibody and surrogate virus neutralization tests to predict neutralizing antibodies against the SARS-CoV-2 Omicron variant following BNT162b2 booster administration

Simon, G., Favresse, J., Gillot, C., Closset, M., Catry, É., Dogné, J., Douxfils, J., Wieërs, G., & Bayart, J. (2023) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-1258 · Cited by 7 · see citing works

Hydroxychloroquine reduces T cells activation recall antigen responses

Kowatsch, M. M., Lajoie, J., Mwangi, L. W., Omollo, K., Oyugi, J. O., Hollett, N. A., Kimani, J., & Fowke, K. R. (2023) · PLoS ONE · doi:10.1371/journal.pone.0287738 · Cited by 6 · see citing works

The mRNA vaccine BNT162b2 demonstrates impaired TH1 immunogenicity in human elders in vitro and aged mice in vivoPreprint

Brook, B., Fatou, B., Checkervarty, A. K., Barman, S., Sweitzer, C., Bosco, A.-N., Sherman, A. C., Baden, L. R., Morrocchi, E., Sánchez‐Schmitz, G., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2395118/v1 · Cited by 6 · see citing works

Kinetics of neutralising antibodies against Omicron variant in Vietnamese healthcare workers after primary immunisation with ChAdOx1-S and booster with BNT162b2Preprint

Chau, N. V. V., Nguyet, L. A., Dung, N. T., Quang, V. M., Truong, N. T., Toan, L. M., Hung, L. M., Man, D. N. H., Khoa, D. B., Phong, N. T., et al. (2022) · medRxiv · doi:10.1101/2022.06.20.22276596 · Cited by 7 · see citing works

Immune Cell Response during COVID-19 Infection and following SARS-CoV-2 Vaccination in Patients Admitted to Intensive Care Unit

Bahrini, K., Stambouli, N., Azaiez, M. B., Rebai, A., Abid, F., Romdhani, C., Labben, I., Gharsallah, H., & Ferjani, M. (2023) · Journal of Immunology Research · doi:10.1155/2023/4059484 · Cited by 5 · see citing works

Correlation of a commercial platform’s results with post-vaccination SARS-CoV-2 neutralizing antibody response and clinical host factors

Slotkin, R., Kyriakides, T. C., Kundu, A., Stack, G. E., Sutton, R. E., & Gupta, S. (2023) · PLoS ONE · doi:10.1371/journal.pone.0289713 · Cited by 4 · see citing works

Immunogenicity and Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (IndoVac®) as a Booster Dose against COVID-19 in Indonesian Adults

Rusmil, K., Fadlyana, E., Girsang, R. T., Adrizain, R., Rahmadi, A. R., Suryadinata, H., Putra, M. G. D., Fulendry, F. P., Nashsyah, D. T., Utami, R. K., et al. (2024) · Vaccines · doi:10.3390/vaccines12050540 · Cited by 3 · see citing works

Robust immunogenicity of a third BNT162b2 vaccination against SARS-CoV-2 Omicron variant in a naïve New Zealand cohort

Lavender, B., Hooker, C., Frampton, C., Williams, M., Carson, S., Paterson, A., McGregor, R., Moreland, N. J., Gell, K., Priddy, F. H., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.07.051 · Cited by 3 · see citing works

The New Modern Medicine

Fuller, J. (2025) · doi:10.1093/9780190066178.001.0001 · Cited by 3 · see citing works

Evaluation of a biotin-based surrogate virus neutralization test for detecting postvaccination antibodies against SARS-CoV-2 variants in sera

Ahn, M.-J., Kang, J., Hong, S. M., Lee, K., Kim, D. H., Song, D., & Jeong, D. G. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.01.052 · Cited by 2 · see citing works

Neutralizing Antibodies against SARS-CoV-2 Beta and Omicron Variants Inhibition Comparison after BNT162b2 mRNA Booster Doses with a New PETIA sVNT Assay

Fogolari, M., Leoni, B. D., Cesaris, M. D., Italiano, R., Davini, F., Miccoli, G. A., Donati, D., Clerico, L., Stanziale, A., Savini, G., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13050889 · Cited by 2 · see citing works

Antibody titers of individuals vaccinated for COVID-19: A systematic review

Domado, A. M., Adaza, H., Beltrán, A. P., Buenviaje, L. M., Co, C. D., Combalicer, L. R., Corona, S. M. A., Cruz, J., Dinjotian, M. A. C. G., Esperanzate, E. M. S., et al. (2023) · Journal of Biosciences · doi:10.1007/s12038-023-00355-1 · Cited by 2 · see citing works

Preclinical evaluation of a SARS-CoV-2 variant B.1.351-based candidate DNA vaccine

Lassaunière, R., Polacek, C., Tingstedt, J. L., & Fomsgaard, A. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.09.021 · Cited by 2 · see citing works

Kinetics of Neutralizing Antibodies against Omicron Variant in Vietnamese Healthcare Workers after Primary Immunization with ChAdOx1-S and Booster Immunization with BNT162b2

Chau, N. V. V., Nguyet, L. A., Dung, N. T., Quang, V. M., Truong, N. T., Toan, L. M., Hung, L. M., Man, D. N. H., Khoa, D. B., Phong, N. T., et al. (2022) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.22-0434 · Cited by 2 · see citing works

Investigating the cause of a 2021 winter wave of COVID-19 in a border region in eastern Germany: a mixed-methods study, August to November 2021

Yi, B., Laubner, A., Stadtmüller, M., Patrasová, E., Šimůnková, L., Rost, F., Winkler, S., Reinhardt, S., Dahl, A., & Dalpke, A. H. (2024) · Epidemiology and Infection · doi:10.1017/s0950268824000761 · Cited by 2 · see citing works

Prevalence and diversity of imported severe acute respiratory syndrome coronavirus 2 variants in China, 2021–2022

Feng, Y., Zhao, X., Chen, Z., Wu, Y., Li, L., Wu, C., Nie, K., Yang, X., Niu, P., Wang, J., et al. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29664 · Cited by 1 · see citing works

Immunogenicity against the Omicron Variant after mRNA-Based COVID-19 Booster Vaccination in Medical Students Who Received Two Primary Doses of the mRNA-1273 Vaccine

Chung, H., Lee, J., Minn, K., Lee, J., Yun, S., Park, J. H., Kim, M., Choi, S., & Chung, J.-W. (2022) · Vaccines · doi:10.3390/vaccines10122102 · Cited by 1 · see citing works

Other Facets of SARS-CoV-2 Immunity, the Risk of Immune Tolerance and T Cell Exhaustion

Mueller, S. (2022) · Springer eBooks · doi:10.1007/978-3-031-18903-6_11 · Cited by 1 · see citing works

Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant

Ávila‐Nieto, C., Vergara‐Alert, J., Amengual-Rigo, P., Ainsua‐Enrich, E., Brustolin, M., de la Concepción, M. L. R., Pedreño-López, N., Rodon, J., Urrea, V., Pradenas, E., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1291972 · Cited by 1 · see citing works

Potential Immunologic and Integrative Methods to Enhance Vaccine Safety

Dattner, A. M. (2022) · Vaccines · doi:10.3390/vaccines10071108 · Cited by 1 · see citing works

SARS-CoV-2 vaccine-induced antibody levels: what lies beneath

Lassaunière, R., & Tiemessen, C. T. (2022) · The Lancet Rheumatology · doi:10.1016/s2665-9913(22)00225-9

Efficacy of a stable multivalent broadly protective subunit vaccine platform against SARS-CoV-2 variants of concernPreprint

Banerjee, A., Garg, R., Liu, Q., van Kessel, J., Asavajaru, A., Uhlemann, E.-M. E., Joessel, M., Hamonic, G., Khatooni, Z., Kroeker, A., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3656968/v1

Preface and Acknowledgments

Fuller, J. (2025) · Oxford University Press eBooks · doi:10.1093/9780190066178.002.0004

The New Medical Model

Fuller, J. (2025) · Oxford University Press eBooks · doi:10.1093/9780190066178.003.0002

Medical Interventions and Risk

Fuller, J. (2025) · Oxford University Press eBooks · doi:10.1093/9780190066178.003.0009

Medical Evidence and Prediction

Fuller, J. (2025) · Oxford University Press eBooks · doi:10.1093/9780190066178.003.0008

The Nature of Chronic Diseases and Mental Disorders

Fuller, J. (2025) · Oxford University Press eBooks · doi:10.1093/9780190066178.003.0006

Therapeutic Skepticism

Fuller, J. (2025) · Oxford University Press eBooks · doi:10.1093/9780190066178.003.0011

Introduction

Fuller, J. (2025) · Oxford University Press eBooks · doi:10.1093/9780190066178.003.0014

Causation and Classification of Disease

Fuller, J. (2025) · Oxford University Press eBooks · doi:10.1093/9780190066178.003.0005

Twenty-First-Century Medicine

Fuller, J. (2025) · Oxford University Press eBooks · doi:10.1093/9780190066178.003.0013

Theories of Contagion and Cancer

Fuller, J. (2025) · Oxford University Press eBooks · doi:10.1093/9780190066178.003.0003

Effect Measures and the Sufficient-Component Cause Model

Fuller, J. (2025) · Oxford University Press eBooks · doi:10.1093/9780190066178.005.0001

Problems of Extrapolation

Fuller, J. (2025) · Oxford University Press eBooks · doi:10.1093/9780190066178.003.0010

Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine

Furukawa, K., Tjan, L. H., Kurahashi, Y., Sutandhio, S., Nishimura, M., Arii, J., & Mori, Y. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.10780 · Cited by 45 · see citing works

Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination

(16544709), S. C., (16553283), C. M., (16559094), Y. L., (16559097), S. N., (16559100), K. C., (12877586), F. K., (7708955), C. C., (15371923), K. Y., (16559103), B. L., (15903800), E. L., et al. (2024) · Figshare · Cited by 2 · see citing works

Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera

Muik, A., Lui, B. G., Wallisch, A.-K., Bacher, M., Mühl, J., Reinholz, J., Ozhelvaci, O., Beckmann, N., Güimil Garcia, R. D. L. C., Poran, A., et al. (2022) · Science · doi:10.1126/science.abn7591 · Cited by 367 · see citing works

mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant

Edara, V. V., Manning, K. E., Ellis, M. L., Lai, L., Moore, K. M., Foster, S. L., Floyd, K. A., Davis-Gardner, M. E., Mantus, G. E., Nyhoff, L. E., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100529 · Cited by 205 · see citing works

Cross-Neutralizing Activity Against Omicron Could Be Obtained in SARS-CoV-2 Convalescent Patients Who Received Two Doses of mRNA Vaccination

Kurahashi, Y., Furukawa, K., Sutandhio, S., Tjan, L. H., Iwata, S., Sano, S., Tohma, Y., Ohkita, H., Nakamura, S., Nishimura, M., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac178 · Cited by 9 · see citing works